{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:18:54Z","timestamp":1785298734188,"version":"3.55.0"},"reference-count":19,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Cosmetic Dermatology"],"published-print":{"date-parts":[[2026,4]]},"abstract":"ABSTRACT<\/jats:title>\n \n Background<\/jats:title>\n \n Repetitive contractions of the platysma muscle may result in vertical neck bands that blunt the jawline (i.e., platysma prominence [\n PP<\/jats:styled-content>\n ]). We report patient\u2010reported outcomes (\n PROs<\/jats:styled-content>\n ) from a phase 2 study evaluating\n onabotulinumtoxinA<\/jats:styled-content>\n (\n onabotA<\/jats:styled-content>\n ) for moderate or severe\n PP.<\/jats:styled-content>\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Subjects were randomized 1:1:1 to\n onabotA<\/jats:styled-content>\n dose 1 (26\u2009U, 31\u2009U, or 36\u2009U),\n onabotA<\/jats:styled-content>\n dose 2 (52\u2009U, 62\u2009U, or 72\u2009U), or placebo. De novo, validated, fit\u2010for\u2010purpose\n PROs<\/jats:styled-content>\n were used to assess treatment satisfaction, bother with vertical neck bands and jawline, jawline definition, and psychosocial impact.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Subjects with PRO data (\n N<\/jats:italic>\n \u2009=\u2009164; mean age, 50.0\u2009years) were predominantly female (95.1%) and White (93.9%). Response rates for improvement in both onabotA dose groups were higher than placebo for treatment satisfaction, bother with vertical neck bands and jawline, as well as jawline definition (unadjusted\n p<\/jats:italic>\n \u2009<\u20090.05 for all). Greater improvements in treatment satisfaction and psychosocial impact were observed in both dose groups versus placebo based on the mean total scores on the Appearance of Neck and Lower Face Questionnaire (ANLFQ): Satisfaction and the mean change from baseline in ANLFQ: Impacts total score, respectively (unadjusted\n p<\/jats:italic>\n \u2009<\u20090.0001 for all). Response rates generally peaked across all measures at day 14 or 30 for both dose groups, with a trend in improvement continuing through day 120.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Compared with placebo, both\n onabotA<\/jats:styled-content>\n dose groups reported greater satisfaction with the effect of treatment, improvements in jawline definition and psychological impact, as well as reductions in bother due to vertical neck bands and jawline.\n <\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n ClinicalTrials.gov: NCT03915067<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/jocd.70821","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T05:16:35Z","timestamp":1775279795000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patient\u2010Reported Outcomes After Treatment With\n OnabotulinumtoxinA<\/scp>\n for Platysma Prominence: Results From a Phase 2 Dose\u2010Ranging Study"],"prefix":"10.1111","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7734-3146","authenticated-orcid":false,"given":"Shannon","family":"Humphrey","sequence":"first","affiliation":[{"name":"Humphrey Cosmetic Dermatology Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya","family":"Shimoga","sequence":"additional","affiliation":[{"name":"AbbVie Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joely","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Skin Associates of South Florida Coral Gables Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bank","sequence":"additional","affiliation":[{"name":"The Center for Dermatology, Cosmetic & Laser Surgery Mount Kisco New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Biesman","sequence":"additional","affiliation":[{"name":"Private Practice Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Harutunian","sequence":"additional","affiliation":[{"name":"AbbVie Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace S.","family":"West","sequence":"additional","affiliation":[{"name":"AbbVie Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Tong","sequence":"additional","affiliation":[{"name":"Allergan Aesthetics, an AbbVie company Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishali","family":"Patel","sequence":"additional","affiliation":[{"name":"AbbVie Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjy179"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0000000000002894"},{"issue":"9","key":"e_1_2_13_4_1","first-page":"931","article-title":"Botulinum Toxin\u2010A Chemical Denervation for Platysmal Bands: Maximal Dosing Considerations","volume":"14","author":"Chen D. L.","year":"2015","journal-title":"Journal of Drugs in Dermatology"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0000000000011472"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.12128"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.10.027"},{"key":"e_1_2_13_8_1","unstructured":"J. K.Garcia J.Whyte M.Gauthier B.Foster C.Foley andV.Patel \u201cDevelopment and validation of patient\u2010reported outcome measures for platysma prominence [poster]. Presented at: Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research; May 7\u201010 2023; Boston MA \u201d."},{"key":"e_1_2_13_9_1","unstructured":"US Food and Drug Administration \u201cGuidance for industry. Patient\u2010reported outcome measures: use in medical product development to support labeling claims \u201daccessed October 7 2025 http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM193282.pdf."},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2025.2537898"},{"key":"e_1_2_13_11_1","unstructured":"US Food and Drug Administration \u201cCollecting patient experience data: how you can best help FDA \u201daccessed April 6 2023 www.fda.gov\/media\/112163\/download."},{"key":"e_1_2_13_12_1","unstructured":"US Food and Drug Administration '\u201cFDA patient\u2010focused drug development guidance series for enhancing the incorporation of the patient's voice in medical product development and regulatory decision making \u201daccessed April 6 2023 https:\/\/www.fda.gov\/drugs\/development\u2010approval\u2010process\u2010drugs\/fda\u2010patient\u2010focused\u2010drug\u2010development\u2010guidance\u2010series\u2010enhancing\u2010incorporation\u2010patients\u2010voice\u2010medical."},{"key":"e_1_2_13_13_1","unstructured":"European Medicines Agency \u201cReinforce patient relevance in evidence generation \u201daccessed April 6 2023 www.ema.europa.eu\/en\/documents\/presentation\/presentation\u2010ema\u2010regulatory\u2010science\u20102025\u2010reinforce\u2010patient\u2010relevance\u2010evidence\u2010generation_en.pdf."},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0000000000003429"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0000000000004695"},{"issue":"12","key":"e_1_2_13_16_1","first-page":"1363","article-title":"Quality of Life and Satisfaction of Patients After Full\u2010Face Injections of Abobotulinum Toxin Type A: A Randomized, Phase IV Clinical Trial","volume":"12","author":"Hexsel D.","year":"2013","journal-title":"Journal of Drugs in Dermatology"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S410621"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp22X720665"},{"key":"e_1_2_13_19_1","unstructured":"American Society of Plastic Surgeons \u201c2020 plastic surgery statistics report \u201daccessed July 25 2023 https:\/\/www.plasticsurgery.org\/documents\/News\/Statistics\/2020\/plastic\u2010surgery\u2010statistics\u2010full\u2010report\u20102020.pdf."},{"key":"e_1_2_13_20_1","unstructured":"American Society of Plastic Surgeons \u201c2022 ASPS procedural statistics release \u201daccessed December 15 2023 https:\/\/www.plasticsurgery.org\/documents\/News\/Statistics\/2022\/plastic\u2010surgery\u2010statistics\u2010report\u20102022.pdf."}],"container-title":["Journal of Cosmetic Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.70821","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jocd.70821","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.70821","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T09:24:40Z","timestamp":1782293080000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jocd.70821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/jocd.70821"],"URL":"https:\/\/doi.org\/10.1111\/jocd.70821","archive":["Portico"],"relation":{},"ISSN":["1473-2130","1473-2165"],"issn-type":[{"value":"1473-2130","type":"print"},{"value":"1473-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-08-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70821"}}